Sanofi Top UK Exec Plans For Hard Brexit, Blasts 'Poor Access' To New Drugs
The managing director for Sanofi in the UK says clinical trials there will become less likely in future if access to innovative drugs doesn't improve, causing comparative standards of care to deteriorate.
You may also be interested in...
A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.
Novo Nordisk's chief says the Danish company is stockpiling medicines in case of "no deal" hard Brexit
Pharmaceutical companies need to get their message over to MPs and MEPs about the risks of Brexit to medicines supply chains, and would do well to work more closely with patient groups to highlight the possible health risks of reduced access to medicines.